A new patent drug for the treatment of Type -2 diabetes——Jinlida Granules
[Functions and Indications]
To tonify qi, nourish yin, fortify the spleen, and transport fluid. Type Ⅱ diabetes mellitus due to dual deficiency of qi and yin, manifested as thirst, increased water and food intake, increased appetite, increased urination, emaciation, fatigue, lack of strength, spontaneous sweating, night sweating, vexing heat in the chest, palms, and soles, and constipation, etc.
Ginseng Radix et Rhizoma, Polygonati Rhizoma, Atractyloadis Rhizoma (stir- baked with bran), Sophorae Flavescentis Radix,Ophiopogonis Radix, Rehmanniae Radix, Polygoni Multiflori Radix Praeparata, Corni Fructus, Poria, Eupatorii Herba, Coptidis Rhizoma,
Anemarrhenae Rhizoma, Epimedii Folium (processed), Salviae Miltiorrhizae Radix et Rhizoma, Puerariae Thomsonii Radix, Litchi Semen, Lycii Cortex.
[Dosage] Take medicine after infusing with hot water, 1 sachet/time, 3 times/day. 8 weeks for a course of treatment, or follow the doctor’s advice.
[Packing] Compound membrane sachet, 9 sachets/box, 120boxes/carton.
[MA Number] License of State Drug Administration Z20050845.
● National Varieties for Medical Insurance Drugs
● National Key New Product
● High-tech Product designated by the Ministry of Science and Technology of the P.R.C
● National Protected Varieties of Traditional Chinese Medicine
Clinical evidence-based study on metformin combined with Jinlida Granules in the treatment of Type-2 diabetes
Leading Hospital: Guang’anmen Hospital, China Academy of Chinese Medical Science (CACMS)
Cooperating Hospitals: Xiyuan Hospital of China Academy of Chinese Medical Science (CACMS), Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Shanxi Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Shanxi University of Traditional Chinese Medicine, Bethune International Peace Hospital, etc.
On the basis of diet control, exercise therapy and stable dose of metformin, combined application of Jinlida Granules can better control the glycosylated hemoglobin in patients with Type-2 diabetes. The Jinlida Granules group had potential therapeutic advantages in reducing waist circumference reducing complications, and improving the functions of islet β – cells.